独家直击！字节跳动试水互动剧业务不到一年 黯然关停多款产品

字节跳动试水互动剧业务不到一年 黯然关停多款产品

北京 - 据可靠消息，字节跳动旗下商业化部门巨量引擎开发的多款探索IAP互动剧小程序业务，包括“泡泡心选”、“爪爪心选”和“果冻心选”，将于2024年6月17日正式关停。这标志着字节跳动进军互动剧领域的尝试以不到一年的时间宣告终结。

此次关停的互动剧产品均以小程序形式内嵌于抖音APP中，由字节跳动旗下公司开发。其中，“果冻心选”和“爪爪心选”由抖音100%控股的北京比特漫步互娱网络信息有限公司开发。这些互动剧需要付费解锁剧情，一个月的会员价格为199元。

业内人士分析，字节跳动此次关停互动剧业务，可能有多方面原因。首先，互动剧的制作成本高昂，但盈利模式尚不明朗。以“我被美女包围了！”为例，其游戏正式版售价42元，如果遇到打折季，价格可以低到35元。而对于互动剧而言，用户只需要花费几十元就可以体验多款作品，因此199元的会员价格对很多用户来说并不具有吸引力。

其次，互动剧的形式可能对用户而言不够新颖。近年来，短视频平台的兴起使得用户习惯了更加碎片化的内容消费，而互动剧的观看形式与传统影视剧类似，对用户吸引力有限。

最后，字节跳动自身业务战略的调整也可能是导致互动剧业务关停的原因之一。近年来，字节跳动在元宇宙、人工智能等领域投入了大量资源，互动剧业务可能并非其未来的发展重点。

尽管字节跳动放弃了互动剧业务，但互动剧这一内容形式本身依然具有一定的发展潜力。未来，随着技术的进步和商业模式的完善，互动剧或许能够迎来新的发展机遇。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.